Prestige Consumer Healthcare Inc. $PBH Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA reduced its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 10.7% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 321,244 shares of the company’s stock after selling 38,654 shares during the quarter. Prestige Consumer Healthcare makes up approximately 1.4% of Leeward Investments LLC MA’s investment portfolio, making the stock its 12th biggest position. Leeward Investments LLC MA’s holdings in Prestige Consumer Healthcare were worth $25,651,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Kayne Anderson Rudnick Investment Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 45.3% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock valued at $135,903,000 after purchasing an additional 493,199 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock valued at $113,635,000 after purchasing an additional 261,537 shares in the last quarter. Congress Asset Management Co. lifted its position in Prestige Consumer Healthcare by 1.8% during the 2nd quarter. Congress Asset Management Co. now owns 1,009,595 shares of the company’s stock worth $80,616,000 after acquiring an additional 18,015 shares in the last quarter. Westwood Holdings Group Inc. lifted its position in Prestige Consumer Healthcare by 7.1% during the 1st quarter. Westwood Holdings Group Inc. now owns 861,282 shares of the company’s stock worth $74,044,000 after acquiring an additional 56,802 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Prestige Consumer Healthcare by 4.8% during the 1st quarter. Northern Trust Corp now owns 852,274 shares of the company’s stock worth $73,270,000 after acquiring an additional 39,198 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $62.27 on Friday. The business’s 50 day moving average is $64.06 and its two-hundred day moving average is $74.64. Prestige Consumer Healthcare Inc. has a 52-week low of $60.15 and a 52-week high of $90.04. The firm has a market cap of $3.06 billion, a price-to-earnings ratio of 14.62, a PEG ratio of 1.97 and a beta of 0.44. The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm had revenue of $249.53 million during the quarter, compared to the consensus estimate of $260.71 million. During the same quarter last year, the firm posted $0.90 earnings per share. Prestige Consumer Healthcare’s revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

PBH has been the topic of several recent research reports. Oppenheimer reduced their price target on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Zacks Research lowered Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Thursday, September 4th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Saturday. Canaccord Genuity Group cut their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Wall Street Zen lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare currently has an average rating of “Hold” and a consensus price target of $90.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.